Supplement S1. Baseline characteristics between the atrial fibrillation detected after stroke (AFDAS) and known atrial fibrillation group.

	AFDAS (n=121)	Known-AF (n=135)	*P*-value
Age (years)	77.2 ± 10.7	77.5 ± 8.9	0.79
Age > 75 years old	83 (68.6)	95 (70.4)	0.76
Male sex	60 (49.6)	73 (45.1)	0.47
Medical history			
Hypertension	87 (71.9)	98 (72.6)	0.91
Diabetes mellitus	36 (29.8)	50 (37.0)	0.22
Current smoking	15 (12.4)	12 (8.9)	0.36
Renal insufficiency	8 (6.6)	19 (14.1)	0.05
Dyslipidemia	14 (11.6)	29 (21.5)	0.03
Previous myocardial infarction	10 (8.3)	10 (7.4)	0.79
Previous PCI	7 (5.8)	11 (8.1)	0.46
Previous CABG	4 (3.3)	3 (2.2)	0.59
Previous heart failure	7 (5.8)	26 (19.3)	<0.01
Previous stroke	23 (19.0)	41 (30.4)	0.04
Echocardiographic parameters			
LVEF (%)	63.2 ± 12.4	60.5 ± 12.5	0.09
LVEF < 50%	15 (12.4)	20 (14.8)	0.57
LAVI > 34 (mL/m²)	94 (77.7)	124 (91.9)	<0.01
E/e' >15	31 (25.6)	36 (26.7)	0.85
Laboratory parameters			
hs-TnI (ng/L)	56.50 ± 32.04	140.86 ± 105.87	0.04
> 99perceintil hs-TnI	53 (43.8)	70 (51.9)	0.19
Hemoglobin (g/dL)	13.5 ± 2.0	13.1 ± 1.8	0.17
Creatinine (mg/dL)	1.0 ± 0.89	1.1 ± 0.46	0.47
LDL cholesterol (mg/dL)	98.3 ± 29.8	94.1 ± 33.3	0.54
Total cholesterol (mg/dL)	164.9 ± 36.6	154.1 ± 40.9	0.03
Initial NIHSS	8.1 ± 5.3	8.5 ± 4.5	0.49
CHA2DS2-VASc Score	5.3 ± 1.3	5.6 ± 1.4	0.19
Reperfusion therapy			
Intravenous thrombolysis	27 (22.3)	34 (25.2)	0.59
Endovascular treatment	11 (9.1)	24 (17.8)	0.04
Medications			
Aspirin	46 (38.0)	27 (20.0)	<0.01
Clopidogrel	28 (23.1)	22 (16.3)	0.17
Warfarin	19 (15.7)	35 (25.9)	0.05
DOAC	37 (30.6)	60 (44.4)	0.02

Statin	99 (81.8)	105 (77.8)	0.42

Values are mean ± standard deviation or n (%)

AF = atrial fibrillation; AFDAS = atrial fibrillation detection after stroke; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft; LVEF = left ventricular ejection fraction; LAVI = left atrium volume index; hs-cTnI = high-sensitive cardiac troponin I; LDL = low density lipoprotein cholesterol; NIHSS = National Institutes of Health stroke scale; DOAC= direct oral anticoagulant

Supplement 2. Comparison of risks of clinical outcomes between the atrial fibrillation detected after stroke (AFDAS) and known atrial fibrillation group.

	AFDAS (n=121)	Known-AF (n=135)	Unadjusted HR (95% CI)	*P*-value	Adjusted HR* (95% CI)	*P*-value
MACCE	33 (27.3)	38 (28.1)	1.01 (0.62-1.63)	0.99	0.96 (0.58-1.59)	0.89
All-cause death	19 (15.7)	19 (14.1)	0.97 (0.50-1.85)	0.91	0.90 (0.46-1.76)	0.76
Heart failure cause readmission	6 (5.0)	14 (10.4)	3.34 (1.09-10.25)	0.04	3.18 (0.99-10.20)	0.05
Stroke cause readmission	14 (11.6)	11 (8.1)	0.77 (0.34-1.75)	0.54	0.75 (0.32-1.73)	0.49

AF = atrial fibrillation; HR = hazard ratio; CI = confidence interval; MACCE = Major Adverse Cerebral Cardiovascular Event (a composite of all-cause death, heart failure cause readmission or stroke cause readmission)

*Adjusted covariates included age >75 years, LVEF < 50%, previous heart failure and previous stroke